Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed two approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; and OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate. The company also develops a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation using its proprietary Guardian Technology. Its product candidates include ARYMO ER and Egalet-002 that are abuse-deterrent, extended-release, oral formulations. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Shionogi Limited to develop, manufacture, and commercialize abuse-deterrent hydrocodone-based product candidates using its technology. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
FDA is also under bit of pressure to get this approval over with so that they meet their yearly targets on the report to congress
Would love for someone to explain the price action on this one for me. They got FDA approval, but didn't get the labels for abuse deterrent that they were after. The early FDA approval also triggered a 40M dollar payout from one of their financiers. The PPS has plummeted since then. Quite an odd one to watch, as usually FDA approval sends stocks upward. I'm genuinely curious about this one, and may buy in if it settles in 6s.
Looks like a case of "buy the rumor, sell the news". Anybody that got in around that Nov bounce has locked in some profits, and down we go. No doubt some late to the party buyers from yesterday are dumping here.
checking on couple swings & wasn't quick enough getting my order in b/f $1.35 halt. Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 - https://finance.yahoo.com/news/egalet-announces-positive-top-line-195000790.html adding - looks not getting in there was a good thing!! Back to say that am keeping this on radar in the morning b/c back up to $1.35 & there is a gap up there to the $2's that just might fill.
EGLT over 5 million shares and 3 million call purchased by tutes in the last month or so. Maybe that float isn't as big as people think?
